Advertisement
Baxter and Claris settle FTC merger challenge by divesting products

Baxter and Claris settle FTC merger challenge by divesting products

By Alex Kacik  |  July 21, 2017

Drugmakers Baxter International and Claris Injectables agreed to divest two pharmaceutical products to settle Federal Trade Commission antitrust concerns over Baxter's proposed $625 million acquisition of Claris' injectable drugs business.

Mallinckrodt will pay $100 million to settle drug monopoly allegations

By Maria Castellucci  |  January 19, 2017

Irish drugmaker Mallinckrodt and its U.S. subsidiary will pay $100 million to settle allegations it illegally hindered competition for a drug used to treat a rare seizure disorder in infants and then significantly raised the price of its product.

FTC sides with Iowa physician assistants in supervision dispute

By Maria Castellucci  |  December 22, 2016

The Federal Trade Commission says Iowa should continue allowing physicians to determine how they will supervise assistants based on their individual practice and the physician assistant's experience. The state medical board wants stricter requirements

Texas Medical Board drops appeal against Teladoc lawsuit

By Dave Barkholz and Erica Teichert  |  October 22, 2016

The Texas Medical Board last week withdrew its appeal against Teladoc's lawsuit that alleges the state's telemedicine rules violate federal antitrust laws, sending the dispute back to a federal trial court.

FTC opposes proposed merger of Mountain States, Wellmont

By Maria Castellucci  |  October 08, 2016

The Federal Trade Commission has recommended that Virginia regulators reject the proposed merger of two large regional systems that operate in the state: Mountain States Health Alliance and Wellmont Health System.

Appeals court ruling gives FTC merger challenges new life

Appeals court ruling gives FTC merger challenges new life

By Erica Teichert  |  October 01, 2016

Recent FTC challenges to hospital mergers have rested on its belief that limiting competition in a well-defined market would harm insurers. Actual prices or their impact on consumers and patients—the traditional grounds for antitrust challenges—barely entered into the equation.

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print